Trump's Psychedelic Executive Order Just Created a New Federal Funding Category. Here's Who Can Access It.

For decades, the most promising compounds in psychiatry sat locked behind Schedule I classification, inaccessible to all but a handful of federally licensed researchers willing to navigate years of DEA paperwork. On April 18, President Trump signed an executive order that fundamentally alters that calculus — directing the FDA, DEA, VA, and ARPA-H to accelerate psychedelic drug research and clear regulatory barriers that have bottlenecked mental health innovation for half a century.

Six days later, the FDA issued its first three Commissioner's National Priority Vouchers to psychedelic candidates. ARPA-H announced 13 research teams splitting up to $139.4 million in behavioral health funding. And the DEA received instructions to begin rescheduling reviews before FDA approval is even finalized.

This isn't incremental reform. It's the creation of an entirely new federal funding category — one that didn't exist three weeks ago.

What the Executive Order Actually Does

The order, titled Accelerating Medical Treatments for Serious Mental Illness, starts with a blunt assessment: over 14 million American adults suffer from serious mental illness, suicide rates climbed 37% between 2000 and 2018, and veterans die by suicide at more than twice the civilian rate. Existing treatments aren't working for a significant share of patients.

The policy response spans five federal agencies:

FDA must issue Commissioner's National Priority Vouchers to psychedelic drugs carrying Breakthrough Therapy designation. On April 24, Commissioner Marty Makary announced three vouchers — to Compass Pathways' psilocybin (COMP360) for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder, and Transcend Therapeutics' methylone (TSND-201) for PTSD. These vouchers compress the standard 10–12 month NDA review timeline to one to two months.

DEA is directed to initiate rescheduling reviews for any product containing a Schedule I substance that has completed Phase 3 trials — critically, before FDA approval, not after. The order also expands Right to Try access, requiring DEA to authorize Schedule I handling for treating physicians and researchers.

ARPA-H must allocate at least $50 million from existing funds to match state government investments in psychedelic research for populations with serious mental illness.

VA is directed to collaborate with HHS and FDA on clinical trial participation and real-world evidence generation, with formal data-sharing memoranda required between agencies. The VA already operates approximately 30 psychedelics studies.

HHS broadly must coordinate interagency collaboration, with the Secretary ensuring federal resources flow toward treatments that have shown clinical promise but been stalled by regulatory classification.

ARPA-H's $139 Million EVIDENT Initiative

The executive order didn't create ARPA-H's behavioral health program from scratch — the Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) initiative launched in late 2024. But the order supercharged it by directing at least $50 million of the total pool toward state-matched psychedelic research.

EVIDENT's core mission is generating FDA-ready clinical endpoints for rapid-acting behavioral health therapies. The agency selected 13 research teams in late April, spanning four technical areas: objective measurement tools, understanding what occurs during treatment, predicting treatment response, and building shared data infrastructure.

The teams with the most direct relevance to psychedelic research:

Johns Hopkins University School of Medicine is contributing data from eight psilocybin clinical trials — the largest single-institution psilocybin dataset being fed into a federal research program. University of Wisconsin brings three approved psilocybin trials plus vagal nerve stimulation data. Diamond Therapeutics, partnered with the Tactical Mind Research Coalition, is feeding a Phase 2a psilocybin trial for generalized anxiety disorder into EVIDENT's measurement framework. University of Southern California is studying psilocybin combined with mindfulness training.

Other teams are tackling adjacent frontiers: Holobiome is investigating gut-brain axis microbiome interventions, Attune Neurosciences is working on low-intensity focused ultrasound neuromodulation, and Yale's Stress Center is studying pregnenolone for alcohol use disorder.

Individual award amounts haven't been disclosed, but ARPA-H has stated that future awards will be made on a rolling basis — meaning this isn't a one-time competition. Teams that missed the first round can still apply.

The State Matching Mechanism

The $50 million ARPA-H allocation for state psychedelic programs introduces a funding structure that doesn't exist elsewhere in federal mental health research: federal matching of state investments.

Texas has already committed $50 million to ibogaine research, and the executive order's matching provision could effectively double that commitment. Other states with active psychedelic legislation — Colorado, Oregon, and Connecticut among them — now have a direct financial incentive to formalize their programs and seek federal partnership.

For researchers and institutions in those states, this creates a two-sided opportunity. State funds can support infrastructure, clinical sites, and investigator time, while federal matching dollars from ARPA-H can cover the measurement and endpoint validation that FDA requires for eventual approval. The practical effect is that a university medical center in a psychedelic-friendly state can now assemble a funding package from sources that, a month ago, didn't exist.

What FDA Priority Vouchers Mean for the Field

The Commissioner's National Priority Vouchers are the fastest regulatory mechanism available short of Emergency Use Authorization. By compressing NDA review to one to two months, they remove the single largest bottleneck in drug development for companies that have already completed clinical trials.

But the vouchers come with important caveats that grant seekers and their institutional partners should understand. First, a voucher is not approval. Full clinical trials demonstrating safety and efficacy are still required. Second, the FDA declined to approve Lykos Therapeutics' MDMA-assisted therapy application in August 2024, citing study design concerns — meaning breakthrough designation doesn't guarantee a smooth path to market.

Third, ibogaine compounds are explicitly mentioned in the executive order despite being at an earlier stage of clinical development and carrying known cardiotoxicity risks. The FDA cleared an early-stage clinical trial for noribogaine hydrochloride (DemeRx's candidate) as a potential treatment for alcohol use disorder, but that's IND clearance, not late-stage review.

For small biotech companies and academic research groups, the practical takeaway is that compounds with Breakthrough Therapy designation now have a dramatically shortened path to market — but only if the underlying trial data is strong. The regulatory acceleration amplifies the importance of rigorous clinical endpoints, which is precisely what ARPA-H's EVIDENT initiative is designed to generate.

Who Can Access This Funding

The executive order and EVIDENT create opportunities across multiple applicant categories:

Academic medical centers with existing psychedelic research programs are the most obvious beneficiaries. Institutions like Johns Hopkins, NYU, UCSF, and the University of Wisconsin already have the infrastructure, IRB approvals, and investigator expertise to compete for ARPA-H awards. The rolling award structure means new proposals can be submitted outside traditional grant cycles.

Biotech companies with Breakthrough Therapy designations or advanced clinical programs gain the most from the FDA voucher mechanism. Compass Pathways, Usona Institute, and Transcend Therapeutics are the first three recipients, but any company whose psychedelic candidate receives Breakthrough designation becomes eligible.

State governments can now pursue federal matching funds for psychedelic research programs. States that have already legalized or decriminalized psilocybin therapy — Oregon and Colorado chief among them — have a head start, but the executive order's language is broad enough to cover states at earlier stages of program development.

Community-based organizations and nonprofits working in veterans' mental health should pay attention to the VA's enhanced mandate. The directive for VA to increase clinical trial participation and generate real-world evidence creates opportunities for organizations that can connect veteran populations with research programs.

International research teams partnered with U.S. institutions may also benefit, though ARPA-H funding flows to domestic entities. Diamond Therapeutics, one of the EVIDENT awardees, is Toronto-based but partnered with the Florida-based Tactical Mind Research Coalition — a model for cross-border collaboration within the federal funding framework.

The Risks and Open Questions

The executive order is bold policy, but several implementation challenges remain unresolved. DEA rescheduling is a formal regulatory process under 21 U.S.C. § 811, and legal scholars have raised questions about the extent of executive authority over controlled substance classification. An executive order can direct the Attorney General to initiate review, but it cannot unilaterally move a substance from Schedule I to Schedule II.

Therapist training and facility requirements for psychedelic-assisted therapy are also undeveloped at scale. Psilocybin sessions typically require six to eight hours of clinical oversight per patient, and there is no existing workforce trained to deliver this at the population level. Funding the science without simultaneously building the delivery infrastructure risks a bottleneck that no executive order can remove.

And the political durability of the order remains uncertain. Executive orders can be rescinded by future administrations, and the psychedelic research ecosystem being built on this foundation will need years — not months — to produce the evidence base that justifies permanent policy changes.

What Happens Next

The immediate timeline is compressed. ARPA-H's rolling EVIDENT awards will continue throughout 2026. FDA is expected to complete its first priority voucher reviews by mid-summer. The DEA's rescheduling process, once initiated, typically takes 12 to 18 months but could be accelerated under the order's directives. And state legislatures currently in session have a narrow window to establish or expand psychedelic programs that qualify for federal matching.

For researchers and institutions that have spent years building psychedelic science programs under hostile federal conditions, the landscape has shifted overnight. The challenge now isn't whether federal funding will flow into this space — it's whether the field can scale fast enough to absorb it responsibly.

Grant seekers tracking emerging federal opportunities across agencies — from ARPA-H to VA to state matching programs — can use Granted to surface psychedelic and behavioral health funding as it becomes available through rolling solicitations.